Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers - PubMed (original) (raw)

Editorial

Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers

Lilian Yan Liang et al. Clin Mol Hepatol. 2023 Jan.

No abstract available

Keywords: Antiviral agents; Hepatitis B; Hepatitis B virus.

Conflict of interest statement

Conflicts of Interest

Lilian Liang declared that she has no competing interests. Vincent Wong has served as a consultant or advisory committee member for AbbVie, Boehringer Ingelheim, Echosens, Intercept, Inventiva, Novo Nordisk, Pfizer, and TARGET PharmaSolutions; and a speaker for Abbott, AbbVie, Gilead Sciences, and Novo Nordisk. He has received a research grant from Gilead Sciences, and is a cofounder of Illuminatio Medical Technology Limited.

Grace Wong has served as an advisory committee member for Gilead Sciences and Janssen, and as a speaker for Abbott, AbbVie, Ascletis, Bristol-Myers Squibb, Echosens, Gilead Sciences, Janssen, and Roche. She has also received a research grant from Gilead Sciences.

Terry Yip has served as an advisory committee member and a speaker for Gilead Sciences.

Comment in

Correspondence on Editorial regarding "HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB".
Mak LY, Seto WK, Yuen MF. Mak LY, et al. Clin Mol Hepatol. 2023 Jan;29(1):191-193. doi: 10.3350/cmh.2022.0410. Epub 2022 Nov 22. Clin Mol Hepatol. 2023. PMID: 36417889 Free PMC article. No abstract available.

Comment on

Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B.
Mak LY, Wong D, Kuchta A, Hilfiker M, Hamilton A, Chow N, Mao X, Seto WK, Yuen MF. Mak LY, et al. Clin Mol Hepatol. 2023 Jan;29(1):146-162. doi: 10.3350/cmh.2022.0172. Epub 2022 Aug 19. Clin Mol Hepatol. 2023. PMID: 35989092 Free PMC article.

References

1. Wong GLH, Gane E, Lok ASF. How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development? J Hepatol. 2022;76:1249–1262. - PubMed
1. Yip TCF, Wong GLH, Chan HLY, Tse YK, Lam KLY, Lui GCY, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol. 2019;70:361–370. - PubMed
1. Yip TC, Wong VW, Tse YK, Chan HL, Wong GL. Hepatitis B surface antigen seroclearance in a cohort of 154,740 patients with chronic hepatitis B: a 15-year follow-up study. Hepatol Int. 2017;11(Suppl 1):S75.
1. Liang LY, Wong VWS, Toyoda H, Tse YK, Yip TCF, Yuen BWY, et al. Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients. J Gastroenterol. 2020;55:899–908. - PubMed
1. Kim SW, Yoon JS, Lee M, Cho Y. Toward a complete cure for chronic hepatitis B: novel therapeutic targets for hepatitis B virus. Clin Mol Hepatol. 2022;28:17–30. - PMC - PubMed

Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers - PubMed (original) (raw)